Personalized and Precision Medicine Journal
Where Innovations Meets Personalized and Precision Medicine

investigation the correlation between FGL1 expression and prognosis in gastric cancer patients

Document Type : Original Article

Authors

Mahnaz Saremi 1
Leila Moezzi 2

1 Reference health laboratory, Ministry of health and medical education

2 Department of Cellular and Molecular, Faculty of Life Sciences, North Tehran Branch, Islamic Azad University, Faculty of Biological Sciences, Tehran, Iran

https://doi.org/10.22034/pmj.2020.240044
Abstract
Gastric cancer is the fourth most common cancer worldwide and it ranks second among cancer deaths. Several studies have shown that FGL2 contributes to the pathogenesis of a number of infectious diseases, However, little is known about its biological functions in cancer development and metastasis. In this study, we investigated the correlation between FGL1 expression and prognosis in GC patients. gastric  cancer tissue  and adjacent healthy pecimens (n=20) were obtained from patients aged between 30 and 50 years who were diagnosed with in gastric cancer, Total RNA was extracted, Reverse transcription and qPCR was performed and Relative expression level was calculated using the 2-∆∆Cq  method. We found that the expression of FGL1 in gastric cancer tissues were obvi­ously higher than that in the adjacent tissues at mRNA levels (p <0.003).

Keywords

Gastric cancer
FGL2 gene
gene expression
qPCR
  1. Sjoquist KM and Zalcberg JR: Gastric cancer: Past progress and present challenges. Gastric Cancer 18: 205‑209, 2015.
  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‑Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 65: 87-108, 2015.
  3. Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin 64: 9-29, 2014.
  4. Lin MT, Lin BR, Chang CC, Chu CY, Su HJ, Chen ST, Jeng YM and Kuo ML: IL‑6 induces AGS gastric cancer cell invasion via activation of the c‑Src/RhoA/ROCK signaling pathway. Int J Cancer 120: 2600-2608, 2007.
  5. Dassen AE, Lemmens VE, van de Poll‑Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, Vd Wurff AA, Bosscha K and Coebergh JW: Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population‑based study in The Netherlands. Eur J Cancer 46: 1101-1110, 2010.
  6. Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and  Győrffy B: Cross‑validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget 7: 49322-49333, 2016.
  7. Yamamoto T, Gotoh M, Sasaki H, Terada M, Kitajima M and Hirohashi S: Molecular cloning and initial characterization of a novel fibrinogen‑related gene, HFREP‑1. Biochem Biophys Res Commun 193: 681-687, 1993.
  8. Demchev V, Malana G, Vangala D, Stoll J, Desai A, Kang HW, Li Y, Nayeb‑Hashemi H, Niepel M, Cohen DE and Ukomadu C: Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization. PLoS One 8: e58084, 2013.
  9. Hara H, Yoshimura H, Uchida S, Toyoda Y, Aoki M, Sakai Y, Morimoto S and Shiokawa K: Molecular cloning and functional Expression analysis of a cDNA for human hepassocin, a liver‑specific protein with hepatocyte mitogenic activity. Biochim Biophys Acta 1520: 45-53, 2001.
  10. Li CY, Cao CZ, Xu WX, Cao MM, Yang F, Dong L, Yu M, Zhan YQ, Gao YB, Li W, et al: Recombinant human hepassocin stimulates proliferation of hepatocytes in vivo and improves survival in rats with fulminant hepatic failure. Gut 59: 817-826, 2010
  11. Livak KJ and Schmittgen TD: Analysis of relative gene expression Data using real‑time quantitative PCR And the 2(‑Delta DeltaC(T)) method. Methods 25:402‑408,2001.

12.Liu Z and Ukomadu C: Fibrinogen‑like protein 1, a hepatocyte derived protein is an acute phase reactant. Biochem Biophys Res Commun 365: 729-734, 2008.

  1. Nayeb‑Hashemi H, Desai A, Demchev V, Bronson RT, Hornick JL, Cohen DE and Ukomadu C: Targeted disruption of fibrinogen like protein‑1 accelerates hepatocellular carcinoma development. Biochem Biophys Res Commun 465: 167-173, 2015.
  2. Yan J, Yu Y, Wang N, Chang Y, Ying H, Liu W, He J, Li S, Jiang W, Li Y, et al: LFIRE-1/HFREP‑1, a liver‑specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma. Oncogene 23: 1939-1949, 2004.
  3. Grunert S, Jechlinger M and Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4: 657‑665, 2003.
  4. Giannelli G, Koudelkova P, Dituri F and Mikulits W: Role of epithelial to mesenchymal transition in hepatocellular carcinoma. J Hepatol65:798-808, 2016.
Personalized and Precision Medicine Journal
Volume 5, Issue 19
Original article
Autumn 2020
Pages 7-9

  • Receive Date 21 December 2020

Home

Publication Ethics

Guide for Authors

Submit Manuscript

Contact Us